Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Today is World Diabetes Day. Stakeholders are concerned by the growing number of people with diabetes who cannot access the ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

PharmaSens announced today that it appointed Dr. Robert A. Gabbay and James L. Peterson to its board of directors.

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Krista Llewellyn was diagnosed with Type 1 diabetes at 12 years old, but she hasn’t let managing her blood sugar levels stop ...

Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.

PORTLAND, GA, UNITED STATES, November 5, 2024 /EINPresswire / -- The global Implantable Insulin Pump Market was pegged at $2.67 billion in 2020, and is estimated to reach $6.44 billion by 2030, ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

PharmaSens, a developer of insulin patch pumps for people with diabetes, has appointed Robert A. Gabbay, MD, PhD, FACP and James L. Peterson to its board of directors.

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...